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Rational design of new cyclic analogues of the
antimicrobial lipopeptide tridecaptin A1†
Ross D. Ballantine, a Yong-Xin Li, b Pei-Yuan Qianb and
Stephen A. Cochrane *a
Non-ribosomal peptides (NRPs) are a rich source of antibiotic candi-
dates. However, it was recently discovered that resistance to NRPs
can be mediated by D-stereoselective peptidases. The tridecaptins, a
class of NRPs that selectively target Gram-negative bacteria, are
degraded by the D-peptidase TriF. Through analysis of a solution
NMR structure of tridecaptin A1, we have rationally synthesized new
cyclic tridecaptin analogues that retain strong antimicrobial activity
and are resistant to TriF.
Antimicrobial resistance is a major global concern. It has been
estimated that if the current rise in infections resulting from
multidrug resistant bacteria is not subdued, by 2050 they will
cause more deaths than cancer.1 Due to the inherent ability of
bacteria to develop resistance mechanisms, new antimicrobial
compounds and targets will always be needed.2 In recent years,
there has been a worrying lack of new antibiotics that target
Gram-negative bacteria.3 These pathogens have an extra layer of
protection in the form of the outer-membrane, which precludes
the entry of many large-scaﬀold antibiotics.4 Several of the Gram-
negative-targeting antibiotics currently undergoing clinical trials
are derivatives of known classes (e.g. b-lactams/b-lactamase
inhibitors) and could therefore be more susceptible to resistance
development.5 Non-ribosomal peptides (NRPs) are becoming
increasingly important in the fight against MDR bacteria, with
many new classes being discovered in recent years.6 D-Amino
acid-containing NRPs (DNRPs) are often resistant to peptidases
as the vast majority of peptidases only cleave L-peptide bonds.
However, recent studies have identified the widespread distribution
of D-stereoselective peptidases. For example, the D-peptidase
BogQ can degrade the DNRPs bacitracin, rampoplanin and
daptomycin, all of which are clinically used antibiotics.
Therefore, D-peptidases could pose a major threat to the long-
evity of NRP antibiotics.7
The tridecaptins are a class of linear DNRPs isolated from
Bacillus and Paenibacillus species.8 Tridecaptin A1 (TriA1) is the
archetypical member of this class and shows strong activity
against Gram-negative bacteria, including multidrug resistant
(MDR) strains of Escherichia coli, Klebsiella pneumoniae and
Acinetobacter baumannii (Fig. 1A).9 TriA1 exerts its bactericidal
eﬀect by binding to lipid II on the inner-membrane and
disrupting the proton-motive force.10 The interaction between
TriA1 and lipid II imbedded in dodecylphosphocholine (DPC)
micelles was recently studied by NMR.10 In the absence of lipid II,
TriA1 adopts a tight hairpin-like amphiphilic structure, however a
more open looped structure is adopted upon lipid II binding
(Fig. 1B). Analysis of this structure suggests that the loop is
stabilized by a p-stacking interaction between D-Trp5 and L-Phe9.
A previously reported alanine scan of TriA1 corroborates the
importance of these residues, as substitution of either D-Trp5 or
L-Phe9 significantly decreases antimicrobial activity.11
The tridecaptins are attractive antibiotic candidates, owing
to their selective activity against Gram-negative bacteria and
ease of preparation by solid-phase peptide synthesis (SPPS).
However, it was recently discovered that the tridecaptins are
hydrolytically cleaved by the D-peptidase TriF at the amide bond
between D-Trp5 and Ser6, rendering them inactive.7 Although
this is likely a self-protection mechanism, similar resistance
mechanisms could develop in more pathogenic bacteria, rendering
these DNRPs inactive. Macrocyclization is often an eﬀective strategy
to improve the stability of peptides towards peptidases.12 However,
N to C cyclization, which is one of the most commonly used
methods to cyclize peptides, is not appropriate for the tridecaptins.
Firstly, they areN-acylated,making N to C cyclizationmore diﬃcult.
Secondly and most importantly, the lipid II-bound conforma-
tion of TriA1 places the N- and C-termini far apart as it wraps
around lipid II on the cell membrane (Fig. 1B). Given that
D-Trp5 and L-Phe9 are in close proximity through a p-stacking
interaction, and that D-Trp5 is cleaved by TriF, we rationalized
that replacement of this p-stacking interaction with a covalent
a School of Chemistry and Chemical Engineering, David Keir Building,
Stranmillis Road, Queen’s University Belfast, Belfast, BT9 5AG, UK.
E-mail: s.cochrane@qub.ac.uk
b Department of Ocean Science and Division of Life Science, Hong Kong University
of Science and Technology, Clear Water Bay, Hong Kong, China
† Electronic supplementary information (ESI) available. See DOI: 10.1039/
c8cc05790g
Received 17th July 2018,
Accepted 17th August 2018
DOI: 10.1039/c8cc05790g
rsc.li/chemcomm
ChemComm
COMMUNICATION
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
Se
pt
em
be
r 2
01
8.
 D
ow
nl
oa
de
d 
on
 9
/1
0/
20
18
 1
1:
23
:2
5 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal
Chem. Commun. This journal is©The Royal Society of Chemistry 2018
linkage could impart resistance to TriF, as well as providing a
new scaﬀold of macrocyclic peptides that specifically target
Gram-negative bacteria. The generation of cyclic TriA1 (cTriA1)
analogues cyclized between these positions would also corro-
borate the importance of the looped secondary structure in the
mechanism of action of this peptide. Herein, we discuss our
synthesis of novel cyclic TriA1 analogues that retain strong
antimicrobial activity and are resistant to the D-peptidase TriF.
Oct-TriA1 (1) was first synthesized by Fmoc-SPPS and tested
against a model Gram-negative (Escherichia coli) and Gram-positive
(Staphylococcus aureus) indicator strain (Table 1). Replacement of
the chiral lipid tail on TriA1 with octanoic acid has no eﬀect on
antimicrobial activity, therefore N-terminal octanoylation was
employed for all analogues.9 Consistent with previous reports,
Oct-TriA1 (1) showed potent activity against E. coli and weak
activity against S. aureus. Our initial eﬀorts to prepare cyclic
TriA1 (cTriA1) analogues focused on replacing the D-Trp5-Phe9
p-stacking interaction with an alkene bridge using on-resin
ring-closing metathesis (RCM). Derksen and Vederas previously
used this strategy to replace a disulfide in the antimicrobial
peptide leucocin A.13 Oct-TriA1-(5-D-Agl, 9-Agl) (2) was synthe-
sized by SPPS, however, the full-length peptide proved refrac-
tory to on-resin RCM. We rationalized that the peptide might be
aggregating, therefore we also attempted the cyclization at the
nonapeptide stage of synthesis. However, this also failed.
Further attempts involving increased catalyst loading, alternate
solvents, increased reaction temperature or chaotropic salts13
were also unsuccessful. We postulated that extension of the
alkene chains as S-allylcysteine (Sac) could facilitate cyclization,
however exposure of Oct-TriA1-(5-D-Sac, 9-Sac) (3) to RCM condi-
tions failed to yield any cyclic product. Neither alkene-containing
peptide showed antimicrobial activityo50 mg mL1, suggesting
that hydrophobic interactions are not suﬃcient to stabilize
the active conformation of TriA1. Previous studies have shown
that not all peptides undergo RCM, with yields often highly
dependent on peptide sequence.14 This situation often arises in
peptides containing a large number of hydrophobic amino
acids.15 Therefore, we believe that the significant hydrophobicity
of the C-terminal region of Oct-TriA1 causes aggregation on-resin
that hinders the RCM reaction. This limitation could be over-
come in solution using an aqueous/organic solvent mix, as
Oct-TriA1 is conformationally flexible in these solvent systems.
11
However, as the vast excess of chaotropic salts required makes
purification diﬃcult,16 we directed our eﬀorts towards an alter-
native cyclization method (Scheme 1).
The cross-linking of cysteine residues is anothermethod used to
staple peptides,17 which has been used to prepare cell-penetrant
inducers of autophagy18 and p53 inhibitors.19 In both studies the
macrocycle ring size aﬀected activity. Therefore, we directed our
eﬀorts towards the generation of cTriA1 analogues with varying
ring-sizes. Oct-TriA1-(5-D-Cys, 9-Cys) (4) was first synthesized by
SPPS. Next, disulfide 5, the smallest possible macrocycle, was
synthesized from dithiol 4 but showed no antimicrobial activity.
Dithiol 4 was then cross-linked with diﬀerent benzylic cross-linkers
to yield Oct-cTriA1 analogues 6–9, which contain increasingly
larger macrocyclic rings. Peptides 6–8, wherein cysteines have
been crosslinked with o-, m- and p-Xyl linkers respectively,
retained strong activity against E. coli (6.3 mg mL1), although
Fig. 1 (A) Structure of TriA1 with TriF cleavage site shown in red. (B) NMR solution structure of TriA1 bound to lipid II (not shown) in DPCmicelles (PDB ID:
2N5W). A p-stacking interaction that may stabilize the looped structure is shown.
Table 1 Antimicrobial activity of linear TriA1 analogues
Peptide
Amino acid MICa
5 9 E. colib S. aureusc
1 D-Trp Phe 0.39 25
2 D-Agl Agl 450 450
3 D-Sac Sac 450 450
4 D-Cys Cys 450 450
a MIC = minimum inhibitory concentration. Determined by microbroth
dilutions assays and experiments run in duplicate. Values are shown to
two significant figures and reported in mg mL1. b Strain NCTC 12241.
c Strain NCTC 10788.
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none were active against S. aureus. Further ring expansion
using a biphenyl linker yielded peptide 9, however this peptide
showed no activity at the highest concentrations tested
(50 mg mL1). Encouraged by these results, we tested the activity
of peptides 6–9 against more clinically significant Gram-
negative bacteria, including Klebsiella pneumoniae, and the
critical tier pathogens Acinetobacter baumannii and Enterobacter
cloacae.20 Gratifyingly, peptides 6–8 showed strong activity
against all strains. Activity against A. baumannii NCTC 13304,
which is a carbapenem resistant strain,21 is particularly promis-
ing as this is currently the WHO’s No. 1 priority pathogen.20
We next attempted to synthesize cTriA1 analogues containing
saturated hydrocarbon cross-links. Performing these reactions
under the same conditions did not yield any cyclic product,
with just linear starting material recovered. Increasing reaction
temperatures thermally, or by microwave irradiation, lead to the
formation of several side-products, including linear peptides in
which one of the cysteine residues had been converted to
dehydroalanine. This likely occurs through bisalkylation of a
single Cys, followed by elimination of the resulting sulfonium.
We therefore moved forward with TriA1 analogues 1–9 to study
their susceptibility to degradation by the D-peptidase TriF.
The D-stereoselective peptidase TriF is a membrane associated
protein found in Paenibacillus polymyxa CICC 10580.7 TriFpep, the
soluble periplasmic peptidase domain of TriF, which lacks the
signal peptide and four hydrophobic transmembrane helices, was
expressed in E. coli BL21 cells as a C-terminal His6-tag protein
construct.7 TriA1 analogues 1–9 were incubated with TriFpep at
37 1C for 12 h and the reaction mixtures analysed by UPLC-MS.
Both Oct-TriA1 (1) and Oct-TriA1(5-D-Sac, 9-Sac) (3) were degraded
by TriFpep (Fig. 2 and Fig. S1, ESI†), whereas Cys analogue 4 and
cTriA1 analogues 5–8 were completely resistant (Fig. 2). We were
unable to test the stability of Oct-cTriA1(biphenyl) (9) as it
is insoluble in the TriF assay mixture. Although 4 and 5
are resistant to TriF, they also have negligible antimicrobial
activity. In contrast, peptides 6–8, which have been crosslinked
with Xyl linkers, retain strong antimicrobial activity and are
resistant to TriF. These analogues therefore represent a new scaffold
of macrocyclic peptides with selective activity against Gram-negative
bacteria. Furthermore, this work highlights the importance
of the p-stacking interaction to TriA1’s mechanism of action.
Scheme 1 Synthesis of novel cyclic analogues of TriA1. MIC = minimum inhibitory concentration. Determined by microbroth dilutions assays and
experiments run in duplicate. Values are shown to two significant figures and reported in mg mL1. a Strain NCTC 12241. b Strain NCTC 10788. c Strain
NCTC 9633. d Strain NCTC 13304. e Strain NCTC 5920.
Fig. 2 Liquid chromatography-mass spectrometry traces of in vitro
assays of TriFpep against Oct-TriA1 (1, black peaks) and o-Xyl- (6, blue
peaks), m-Xyl- (7, green peaks) and p-Xyl- (8, red peaks) crosslinked
peptides. Standards (black line) without TriFpep and experiments with
TriFpep (red line) are shown. Whereas Oct-TriA1 is cleaved by TriFpep, no
corresponding cleavage was observed in TriFpep treated 6–8.
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Improvements in the antimicrobial activity of the cTriA1 analo-
gues should be possible through further structure–activity
relationship studies.
In conclusion, we have employed a rational design approach
to generate new cyclic analogues of tridecaptin A1 that are
resistant to the D-peptidase TriF. Analysis of an NMR solution
structure of TriA1 identified a possible cyclization point
between positions 5 and 9, which are in close proximity due
to a p-stacking interaction. Substitution of D-Trp5 and L-Phe-9
with D-Cys and L-Cys respectively, followed by cross-linking with
benzylic di-bromo linkers yielded cyclic TriA1 analogues that
retain selective activity against Gram-negative bacteria and are
resistant to TriF. To the best of our knowledge, the replacement
of p-stacking interactions with a covalent linkage to impart
peptidase stability is a novel strategy. These structures constitute
a new class of Gram-negative-targeting macrocyclic peptides and
could be the basis for new antibiotic candidates.
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